Bristol Myers Squibb said Tuesday that an oral drug designed to treat psoriasis differently from currently approved medicines demonstrated superiority to placebo and a competing drug from Amgen — achieving the goals of a large Phase 3 clinical trial.
The safety profile of the Bristol drug called deucravacitinib, was “consistent” with previously conducted studies, the company added.
About the Author Reprints
